olivLaw · US equity research
Eli Lilly and Company LLY
Pharmaceutical Preparations · SIC 2834
Eli Lilly and Company is a pharmaceutical company operating in a single segment, human pharmaceutical products. Revenue rose 48% in the second quarter of 2026 to 22.974 billion USD, and full-year 2026 revenue guidance was raised to 85.0-87.0 billion USD. Growth is driven mainly by Mounjaro and Zepbound, but pressure on realized prices and acquisition charges could affect margins.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Eli Lilly and Company (LLY) stock was 1,417.99 USD (+0.61% on the day), with market capitalisation 1,334.0 bn USD, P/E 46.0 on diluted EPS of 30.81 USD over the last 12 months, dividend yield 0.47%, beta 0.54, 52-week range 851.21–1,417.99 USD. Latest reported quarter (Q3 2026): revenue of 24.4 bn USD (+38.6% YoY), net income of 6.5 bn USD (+15.5% YoY), diluted EPS 7.22 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 76.6
- overbought (≥ 70)
- Bollinger (20, 2)
- 1,119.75 – 1,447.17
- in the upper half of the band · %B 0.91 · band width 25.5%
- SMA 50 / 200
- 1,207.19 / 1,096.87
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 59.23 / 44.06
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +24.0% | −1.1% | +25.1 pp | — |
| 3 months | +21.2% | −0.5% | +21.7 pp | — |
| 6 months | +43.7% | +4.4% | +39.3 pp | — |
| Year to date | +31.9% | +12.3% | +19.6 pp | — |
| 1 year | +56.4% | +13.5% | +42.8 pp | — |
| 3 years | +149.7% | +76.4% | +73.3 pp | — |
| 5 years | +435.1% | +63.7% | +371.4 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q3 2026 · 30 Sept 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13.5 bn | 12.7 bn | 15.6 bn | 17.6 bn | 19.3 bn | 19.8 bn | 23.0 bn | 24.4 bn |
| Cost of revenue | 2.4 bn | 2.2 bn | 2.4 bn | 3.0 bn | 3.4 bn | 3.6 bn | 3.3 bn | 3.9 bn |
| SG&A | 2.4 bn | 2.5 bn | 2.8 bn | 2.7 bn | 3.1 bn | 2.9 bn | 3.4 bn | 3.1 bn |
| Depreciation & amortisation | 485.2 m | 463.0 m | 478.0 m ≈ | 470.0 m ≈ | 586.0 m | 509.0 m | 534.0 m ≈ | 545.0 m ≈ |
| Interest expense | 225.1 m | 243.7 m | 249.0 m | 179.6 m | 222.6 m | — | — | — |
| Pre-tax income | 5.0 bn | 3.5 bn | 6.8 bn | 7.2 bn | 8.3 bn | 8.9 bn | 9.2 bn | 8.4 bn |
| Income tax | 628.5 m | 697.0 m | 1.1 bn | 1.7 bn | 1.6 bn | 1.5 bn | 2.2 bn | 2.0 bn |
| Net income | 4.4 bn | 2.8 bn | 5.7 bn | 5.6 bn | 6.6 bn | 7.4 bn | 7.1 bn | 6.5 bn |
| Diluted EPS | 4.88 ≈ | 3.06 | 6.29 | 6.21 | 7.39 ≈ | 8.26 | 7.94 | 7.22 |
| Operating cash flow | 2.5 bn | 1.7 bn | 3.1 bn ≈ | 8.8 bn ≈ | 3.2 bn | 5.3 bn | 10.7 bn ≈ | 11.4 bn ≈ |
| Dividends paid | 1.2 bn | 1.3 bn | 1.3 bn ≈ | 1.3 bn ≈ | 1.3 bn | 1.5 bn | 1.5 bn ≈ | 1.5 bn ≈ |
| Share repurchases | 2.1 bn | 1.2 bn | 692.0 m ≈ | 708.0 m ≈ | 1.5 bn | 2.4 bn | 1.6 bn ≈ | 377.0 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 62 percentile of its own 42-quarter history (min 13.6, median 38.9, max 238.5; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.5 bn | 22.3 bn | 24.5 bn | 28.3 bn | 28.5 bn | 34.1 bn | 45.0 bn | 65.2 bn |
| Revenue YoY | +7.6% | +3.8% | +9.9% | +15.4% | +0.8% | +19.6% | +32.0% | +44.7% |
| Net income | 3.2 bn | 8.3 bn | 6.2 bn | 5.6 bn | 6.2 bn | 5.2 bn | 10.6 bn | 20.6 bn |
| Net income YoY | unavailable | +157.4% | −25.5% | −9.9% | +11.9% | −16.1% | +102.1% | +94.9% |
| Diluted EPS | 3.13 | 8.89 | 6.79 | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 |
| Diluted EPS YoY | unavailable | +184.0% | −23.6% | −9.9% | +12.7% | −15.9% | +101.9% | +96.0% |
| net % | 15.0% | 37.3% | 25.2% | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| Free cash flow | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 7.3 bn USD
- Financial debt
- 42.5 bn USD
- Net debt
- 35.2 bn USD
- Equity
- 26.5 bn USD
- Total assets
- 112.5 bn USD
- Debt / equity
- 1.60x
- Current ratio
- 1.58x
- ROE
- 101.2%
- ROA
- 21.6%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 24.5 bn | 28.3 bn | 28.5 bn | 34.1 bn | 45.0 bn | 65.2 bn | SEC (XBRL)· 12 Feb 2026verified |
| Cost of revenue | 5.5 bn | 7.3 bn | 6.6 bn | 7.1 bn | 8.4 bn | 11.1 bn | SEC (XBRL)· 12 Feb 2026verified |
| Gross profit | 19.1 bn ≈ | 21.0 bn ≈ | 21.9 bn ≈ | 27.0 bn ≈ | 36.6 bn ≈ | 54.1 bn ≈ | SEC (XBRL)· 12 Feb 2026derived |
| Research & development | 6.0 bn | 6.9 bn | 7.2 bn | — | — | — | SEC (XBRL)· 22 Feb 2023verified |
| SG&A | 6.1 bn | 6.4 bn | 6.4 bn | 7.4 bn | 8.6 bn | 11.1 bn | SEC (XBRL)· 12 Feb 2026verified |
| Depreciation & amortisation | 1.3 bn | 1.5 bn | 1.5 bn | 1.5 bn | 1.8 bn | 2.0 bn | SEC (XBRL)· 12 Feb 2026verified |
| Interest expense | 359.6 m | 339.8 m | 331.6 m | 485.9 m | 781.0 m | 895.0 m | SEC (XBRL)· 12 Feb 2026verified |
| Pre-tax income | 7.2 bn | 6.2 bn | 6.8 bn | 6.6 bn | 12.7 bn | 25.7 bn | SEC (XBRL)· 12 Feb 2026verified |
| Income tax | 1.0 bn | 573.8 m | 561.6 m | 1.3 bn | 2.1 bn | 5.1 bn | SEC (XBRL)· 12 Feb 2026verified |
| Net income | 6.2 bn | 5.6 bn | 6.2 bn | 5.2 bn | 10.6 bn | 20.6 bn | SEC (XBRL)· 12 Feb 2026verified |
| Diluted EPS | 6.79 | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 | SEC (XBRL)· 12 Feb 2026verified |
| Weighted average diluted shares | 912.5 m | 911.7 m | 904.6 m | 903.3 m | 904.1 m | 899.3 m | SEC (XBRL)· 12 Feb 2026verified |
| Dividend per share | 3.07 | 3.53 | 4.07 | 4.69 | 5.40 | 6.23 | SEC (XBRL)· 12 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 3.7 bn | 3.8 bn | 2.1 bn | 2.8 bn | 3.3 bn | 7.3 bn | SEC (XBRL)· 12 Feb 2026verified |
| Receivables | 5.9 bn | 6.7 bn | 6.9 bn | 9.1 bn | 11.0 bn | 17.8 bn | SEC (XBRL)· 12 Feb 2026verified |
| Inventories | 4.0 bn | 3.9 bn | 4.3 bn | 5.8 bn | 7.6 bn | 13.7 bn | SEC (XBRL)· 12 Feb 2026verified |
| Current assets | 17.5 bn | 18.5 bn | 18.0 bn | 25.7 bn | 32.7 bn | 55.6 bn | SEC (XBRL)· 12 Feb 2026verified |
| Property, plant & equipment, net | 8.7 bn | 9.0 bn | 10.1 bn | 12.9 bn | 17.1 bn | 24.7 bn | SEC (XBRL)· 12 Feb 2026verified |
| Goodwill | 3.8 bn | 3.9 bn | 4.1 bn | 4.9 bn | 5.8 bn | 5.9 bn | SEC (XBRL)· 12 Feb 2026verified |
| Intangibles (excl. goodwill) | 7.5 bn | 7.7 bn | 7.2 bn | 6.9 bn | 6.2 bn | 6.5 bn | SEC (XBRL)· 12 Feb 2026verified |
| Total assets | 46.6 bn | 48.8 bn | 49.5 bn | 64.0 bn | 78.7 bn | 112.5 bn | SEC (XBRL)· 12 Feb 2026verified |
| Accounts payable | 1.6 bn | 1.7 bn | 1.9 bn | 2.6 bn | 3.2 bn | 5.4 bn | SEC (XBRL)· 12 Feb 2026verified |
| Short-term debt | 8.7 m | 1.5 bn | 1.5 bn | 6.9 bn | 5.1 bn | 1.6 bn | SEC (XBRL)· 12 Feb 2026verified |
| Long-term debt | 16.6 bn | 15.3 bn | 14.7 bn | 18.3 bn | 28.5 bn | 40.9 bn | SEC (XBRL)· 12 Feb 2026verified |
| Current liabilities | 12.5 bn | 15.1 bn | 17.1 bn | 27.3 bn | 28.4 bn | 35.2 bn | SEC (XBRL)· 12 Feb 2026verified |
| Equity | 5.8 bn | 9.2 bn | 10.8 bn | 10.9 bn | 14.3 bn | 26.5 bn † | SEC (XBRL)· 12 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 6.5 bn | 7.4 bn | 7.6 bn | 4.2 bn | 8.8 bn | 16.8 bn | SEC (XBRL)· 12 Feb 2026verified |
| Investing cash flow | -2.3 bn | -2.9 bn | -3.8 bn | -7.2 bn | -9.3 bn | -11.0 bn | SEC (XBRL)· 12 Feb 2026verified |
| Financing cash flow | -3.1 bn | -4.1 bn | -5.4 bn | 3.5 bn | 1.2 bn | -2.2 bn | SEC (XBRL)· 12 Feb 2026verified |
| Dividends paid | 2.7 bn | 3.1 bn | 3.5 bn | 4.1 bn | 4.7 bn | 5.4 bn | SEC (XBRL)· 12 Feb 2026verified |
| Share repurchases | 500.0 m | 1.3 bn | 1.5 bn | 750.0 m | 2.5 bn | 4.1 bn | SEC (XBRL)· 12 Feb 2026verified |
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1,334.0 bn USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/Eunavailable · not enough peers
- Dividend discount (DDM)outside the aggregate81.87 – 110.10 (Mid 93.91)a small share of earnings is paid as dividends (capital returns through buybacks): the dividend model does not describe the value and stays outside the aggregate
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | 31.9% | 100 (on a fixed band) | 14% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 31.7% | 100 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | 49.3% | 100 (on a fixed band) | 19% |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.4x | 49 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | 46.0x | 0 (on a fixed band) | 24% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | 0.9% | 13 (on a fixed band) | 14% |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial49/100 · 1/3 factors with a value
- Growth100/100 · 2/2 factors with a value
- Quality· partial100/100 · 1/3 factors with a value
- Returns· partial13/100 · 1/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ELI LILLY AND COMPANY (LLY). Latest full fiscal year: 2025; data up to 2026-09-30.
Figures computed from the financial statements: revenue 65.2 bn USD in 2025; YoY growth 44.7%; net margin 31.9%; ROE 86.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Net margin: 31.9%
- Revenue CAGR 3Y: 31.7%
- EPS CAGR 3Y: 49.3%
What contradicts it
- P/E (TTM): 46.0x
- Shareholder yield (distributions): 0.9%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Net debt / EBITDA, Interest coverage, EV/EBITDA, FCF yield, Payout ratio (FCF).
Versus the vertical median
Not enough comparable companies with data for an average.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 881.68 Total return -37% · Per year -37% | 1,551.63 Total return 10% · Per year 10% | 2,327.44 Total return 65% · Per year 65% |
| 3 years | 1,045.81 Total return -25% · Per year -9% | 2,052.02 Total return 47% · Per year 14% | 3,351.51 Total return 139% · Per year 34% |
| 5 years | 1,240.50 Total return -10% · Per year -2% | 2,713.80 Total return 95% · Per year 14% | 4,826.17 Total return 245% · Per year 28% |
- Exit P/E± 513.01
- Net margin± 359.10
- Annual revenue growth± 267.82
- Annual dilution± 30.17
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 10-Q (29 Oct 2026), 8-K (29 Oct 2026 · results).
In brief
Eli Lilly and Company is a pharmaceutical company operating in a single segment, human pharmaceutical products. Revenue rose 48% in the second quarter of 2026 to 22.974 billion USD 23, and full-year 2026 revenue guidance was raised to 85.0-87.0 billion USD 3. Growth is driven mainly by Mounjaro and Zepbound, but pressure on realized prices and acquisition charges could affect margins.
SWOT
Strengths
- The company holds a strong position in incretin medicines and has grown revenue rapidly 23.
- Gross margin rose in 2026, supported by better production costs and a favorable product mix 3.
- The portfolio spans four therapeutic areas with products approved in the United States, the European Union and Japan 1.
Weaknesses
- A large share of revenue depends on a few products, which increases exposure to changes in demand or pricing 1.
- Realized prices have fallen, and changes in the U.S. and abroad could reduce revenue per unit 23.
- Acquisitions and external collaborations can bring large IPR&D charges and affect profit in a given period 3.
Opportunities
Risks
- Pricing and access pressurehigh
Price and reimbursement restrictions, as well as commitments with the U.S. government, could reduce revenue per unit 12.
- Uncertain research and developmenthigh
Most candidates never reach the market, and approvals and launches can be delayed 1.
- Generic and biosimilar competitionmedium
After exclusivity ends, products can quickly lose a significant part of their revenue 1.
- Tariffs and supply chainmedium
New or reinstated tariffs could raise costs and disrupt supply 2.
- Litigation and regulationmedium
Litigation over pricing, insulin and the 340B program, along with compliance issues, can carry financial and reputational effects 1.
Investment thesis
What would need to be true (bull case)
- Rapid revenue growth from incretin medicines and raised 2026 guidance point to solid demand for products 23.
- Rising gross margin and investment in production could support profitability over the medium term 3.
- Pipeline progress, including retatrutide clinical data and the orforglipron approval, could open new revenue sources 23.
What would break the thesis
- Realized prices have fallen, and reduced access in some markets could limit growth 23.
- Acquisitions and IPR&D charges can reduce net income in a period and raise questions about the return on these investments 3.
- Reliance on a few products could amplify the impact of a change in policy, competition or regulation 1.
What to watch
- Realized prices and U.S. access after the Medicare GLP-1 Bridge programQ3 2026
- Submission of the Biologics License Application for retatrutide to the FDAQ1 2027
- Updated full-year 2026 guidance for revenue and non-GAAP EPSnext 10-Q
- Integration of recent acquisitions and their effect on IPR&D charges2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 05 Aug 2026; since then the company filed 10-Q (29 Oct 2026), 8-K (29 Oct 2026 · results).
The business
In the United States most products are distributed through wholesalers, and three wholesale distributors each accounted for a significant share of consolidated revenue in 2023, 2024 and 2025 1. The company has expanded LillyDirect, its direct-to-patient platform, whose share of the business grew in 2025 1. Some products are also marketed through arrangements with other pharmaceutical companies 1.
Main therapeutic areas are cardiometabolic health, oncology, immunology and neuroscience 1. Cardiometabolic products such as Mounjaro, Zepbound, Jardiance and insulins make up the largest part of revenue 13, and the pipeline includes candidates such as orforglipron and retatrutide 12.
Segments
Cardiometabolic health
Mounjaro and Zepbound accounted for 56% of total revenue in fiscal 2025 1. In the second quarter of 2026 Mounjaro generated 9.943 billion USD and Zepbound 4.928 billion USD 3. Orforglipron, an oral candidate for obesity and type 2 diabetes, has been submitted and approved for obesity 2.
Market context
Trends
- Strong demand for incretin medicinestailwind
Demand for Mounjaro and Zepbound has grown strongly and drove quarterly revenue growth 23. If this demand persists, it could support further expansion of manufacturing capacity 1.
- Pricing pressureheadwind
Governments and private payers restrict prices and patient access, and negotiations with the U.S. government could reduce revenue in some markets 12. Government price setting under the IRA for products such as Jardiance, Trulicity and Verzenio could shape longer-term trends 12.
- Acquisitions and the pipelinemixed
Acquisitions completed in and after the second quarter brought significant acquired IPR&D charges but could expand the pipeline in obesity and infectious disease 3. The effect depends on clinical results and future approvals 1.
- Tariffs and the supply chainmixed
Tariffs can be imposed or paused quickly, and the company may not be able to pass on all added costs 12. Expanding production capacity, including the additional investment in Indiana, partly mitigates this risk 3.
Competitive position
Lilly competes with many multinational pharmaceutical, biotechnology and generic companies, and competition from China has intensified 1. Generic and biosimilar products can quickly reduce revenue of products that lose exclusivity 1.
Competitive factors include effectiveness, safety, patient access, formulary placement and price, and early market entry can be decisive 1. New treatment modalities can reduce sales of existing products 1.
- Novo Nordisk
Named in the analysed sources as an actor in incretin therapies for obesity and diabetes; no ticker is given in the sources.
- Large multinational pharmaceutical companies
The sources describe general competition from large pharmaceutical companies without a complete named list.
- Generic and biosimilar manufacturers
Competition from generics and biosimilars can become intense after exclusivity ends, according to the sources.
- Biotechnology and Chinese companies
The sources flag expanding research capacity in China and licensing of products to multinational companies.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- STAT+: Ultragenyx cuts staff after another study failsSTAT News · 04 Nov 2026 · EN
- Ireland fact of the dayMarginal Revolution · 03 Nov 2026 · EN
- Santoli: AI bull market almost surely needs tech stocks to recover to keep advancingCNBC — Top News · 03 Nov 2026 · EN
- This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?Nature · 03 Nov 2026 · EN
- Rezultate financiare record pentru gigantul Eli Lilly: veniturile au urcat cu 39%, la peste 24 de miliarde de dolari, impulsionate de tratamentele cardiometaboliceLibertatea.ro · 02 Nov 2026 · RO
- STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and moreSTAT News · 02 Nov 2026 · EN
- Pharma's next cash cows could be specialized treatmentsAxios · 02 Nov 2026 · EN
- Un tratament anti-obezitate ajunge în farmaciile din Franța, sub formă de tableteMediafax · 02 Nov 2026 · RO
- Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trialsNature Medicine · 02 Nov 2026 · EN
- Global, regional and national burden of cervical cancer in 1990–2023 with forecasts to 2050: a Global Burden of Disease studyNature Medicine · 02 Nov 2026 · EN
- Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trialNature Medicine · 02 Nov 2026 · EN
- Everyone is thin and we’re not allowed to say so: the toxic legacy of body positivityThe Guardian — Health · 30 Oct 2026 · EN
- Уолл-стрит снизилась в четверг вслед за акциями AlphabetInterfax Russia (RU) · 30 Oct 2026 · RU
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls onCNBC — Top News · 29 Oct 2026 · EN
- Stocks making the biggest moves midday: ADT, Alphabet, Caterpillar, Eli Lilly, Chipotle & moreCNBC — Top News · 29 Oct 2026 · EN
- Eli Lilly Shares Surge on Raised Sales ForecastBloomberg Markets · 29 Oct 2026 · EN
- Stocks making the biggest moves premarket: Alphabet, Caterpillar, Eli Lilly, DoorDash & moreCNBC — Top News · 29 Oct 2026 · EN
- Фармацевтическая Eli Lilly в III квартале увеличила выручку на 39%Interfax Russia (RU) · 29 Oct 2026 · RU
- Eli Lilly is about to report earnings. Here's what to expectCNBC — Top News · 29 Oct 2026 · EN
- 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trialNature Medicine · 29 Oct 2026 · EN
SEC filings
- Quarterly report29 Oct 2026
- Current report29 Oct 2026Results of operations · Financial statements and exhibits
- Quarterly report05 Aug 2026
- Current report05 Aug 2026Results of operations · Financial statements and exhibits
- Current report20 May 2026Other events · Financial statements and exhibits
- Current report07 May 2026Shareholder vote
- Quarterly report30 Apr 2026
- Current report30 Apr 2026Results of operations · Financial statements and exhibits
- Proxy statement20 Mar 2026
- Annual report12 Feb 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Eli Lilly and Company · 12 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Eli Lilly and Company · 05 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Eli Lilly and Company · 05 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.